Related Experiment Videos
Risk identification using structural concepts: the potential carcinogenicity of praziquantel
H S Rosenkranz1, Y P Zhang, G Klopman
1Department of Environmental and Occupational Health, University of Pittsburgh, Pennsylvania 15238, USA.
Regulatory Toxicology and Pharmacology : RTP
|October 1, 1995
Summary
Praziquantel (PZ) may be a nongenotoxic carcinogen in rodents, posing minimal human risk. Its benefits against widespread parasitic diseases outweigh potential harm, especially as it replaced genotoxic agents.
Area of Science:
- Toxicology
- Pharmacology
- Drug Safety
Background:
- Praziquantel (PZ) is a crucial antiparasitic drug.
- Previous agents used to treat parasitic diseases were genotoxic rodent carcinogens.
- Assessing the carcinogenic potential of PZ is vital for public health.
Purpose of the Study:
- To evaluate the carcinogenic potential of praziquantel (PZ) in rodents.
- To assess the risk posed by PZ based on its structural features.
- To compare the risk of PZ with previously used genotoxic antiparasitic agents.
Main Methods:
- Utilized the structure-activity relational expert system (CASE/MULTICASE).
- Analyzed structural features of PZ for carcinogenic potential.
- Classified potential carcinogenicity as "nongenotoxic" or "genotoxic".
Main Results:
- PZ exhibits structural features suggesting potential as a "nongenotoxic" carcinogen in rodents.
- Nongenotoxic carcinogens are considered to pose a significantly lower risk to humans than genotoxic ones.
- PZ has proven therapeutic efficacy against parasitic infections affecting millions globally.
Conclusions:
- The potential risk of PZ as a nongenotoxic carcinogen is low.
- PZ offers significant therapeutic benefits for widespread parasitic diseases.
- PZ is a safer alternative to older antiparasitic drugs that were genotoxic rodent carcinogens.